Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNSC Transplantation for Hemorrhagic Stroke
NCT03725865Phase 1Unknown
- Sponsor
- Allife Medical Science and Technology
- Start
- Mar 2019
- Primary completion
- Mar 2019
01
Overview
Phase 1, open-label, single-arm trial of iPS-NSC in hemorrhagic stroke, sponsored by Allife Medical Science and Technology. Primary endpoint: Incidence of Treatment Emergent Adverse Events at 1 year. Status: unknown.
02
Drugs
iPS-NSC
03
Conditions
hemorrhagic stroke
Beyond the preview
Go deeper on NCT03725865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03725865.